CXR1002

CXR1002 is a small molecule ammonium salt of perfluorooctanoic acid (PFOA) that was developed by CXR Drug Discovery as an antineoplastic agent. It acts as a fatty acid mimetic and modulates the activity of peroxisome proliferator-activated receptors (PPARs), specifically functioning as an agonist for PPARα and PPARγ and an antagonist for PPARδ. The drug's primary mode of action involves the induction of endoplasmic reticulum (ER) stress, leading to pro-apoptotic and anti-proliferative effects in a variety of human cancer cells, including pancreatic, ovarian, colorectal, and prostate carcinomas. CXR1002 has been evaluated in Phase I clinical trials for patients with advanced solid tumors, where it demonstrated a unique pharmacokinetic profile and potential synergy with other chemotherapeutic agents like gemcitabine and doxorubicin.

Other names

ammonium perfluorooctanoateAPFO